.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,473,761

« Back to Dashboard

Claims for Patent: 7,473,761

Title:Somatostatin analogues
Abstract: The invention provides cyclo[{4-(NH.sub.2--C.sub.2H.sub.4--NH--CO--O--)Pro}-Phg-DTrp-Lys-Tyr(4-B- enzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.
Inventor(s): Albert; Rainer (Basel, CH), Bauer; Wilfried (Lampenberg, CH), Bodmer; David (Klingnau, CH), Bruns; Christian (Freiburg, DE), Felner; Ivo (Reinach, CH), Hellstern; Heribert (Heitersheim, DE), Lewis; Ian (Riehen, CH), Meisenbach; Mark (Durmenach, FR), Weckbecker; Gisbert (Biel-Benken, CH), Wietfeld; Bernhard (Efringen-Kirchen, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:10/343,288
Patent Claims: 1. A compound of formula ##STR00002## where one of the amino groups being optionally in protected form, or a salt or complex thereof.

2. A compound according to claim 1 in unprotected form, in salt form.

3. A compound according to claim 2 as a mono- or disalt.

4. A compound according to claim 3 in the form of an acetate, benzoate, aspartate or pamoate salt.

5. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof, in association with one or more pharmaceutically acceptable diluent(s) or carrier(s) therefor.

6. A pharmaceutical composition according to claim 5, in a sustained release form or in a topical form.

7. A pharmaceutical composition according to claim 5, for use in combination with an immunosuppressive agent, an anti-inflammatory agent, a GH secretagogue receptor modulating agent, a GH receptor antagonist, an insulin secretagogue, an insulin secretion enhancer, an insulin sensitizer, a low dose of insulin, an agent having anti-angiogenetic effects or a chemotherapeutic agent.

8. A compound of formula ##STR00003## where one of the amino groups being optionally in protected form, or a salt or complex thereof and R.sup.1 is a chelating agent, optionally complexed with a detectable or a radiotherapeutic element.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc